Market Place
Sourcing Support
Lumen Bio`s LMN-201: 100% Initial C. difficile Cure in RePreve Trial
03 Apr 2025 //
PR NEWSWIRE
Lumen gets $16M for C. diff drug; Flashpoint’s seed round
17 Oct 2023 //
ENDPTS
Lumen Bioscience Awarded $8.8 million from U.S. Department of Defense
11 May 2023 //
PR NEWSWIRE
Lumen Bio Announces Clinical Advancement of LMN-201 for C. difficile Infection
18 Apr 2022 //
PRNEWSWIRE
Lumen Bio Publishes Detailing of Spirulina-Based Platform on Large-Scale
21 Mar 2022 //
PRNEWSWIRE
Lumen lands another DoD contract to treat Covid-related GI issues
09 Oct 2021 //
ENDPTS
Lumen Bioscience Awarded Federal Funding to Advance Covid-19 Antibody
06 Oct 2021 //
PRNEWSWIRE
Lumen Bioscience, Google Partner to Apply ML to Biologics Manufacturing
11 Aug 2021 //
CONTRACT PHARMA
Lumen teams with Google to help grow drug-producing algae
11 Aug 2021 //
FIERCE PHARMA
Lumen is taking over a bakery to grow proteins in spirulina
23 Jul 2021 //
FIERCEPHARMA
Lumen Bioscience Expands Biologics Manufacturing Capacity
15 Jul 2021 //
PR NEWSWIRE
Lumen Bioscience and Novo Nordisk Enter into Research Collaboration
16 Jun 2021 //
PRNEWSWIRE
Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors
08 Oct 2020 //
PRNEWSWIRE
Lumen bags U.S. grant for GI-focused COVID-19 antibody cocktail
24 Sep 2020 //
FIERCE BIOTECH
With a $4M federal grant, Lumen jumps into the Covid-19 treatment race
24 Sep 2020 //
ENDPTS
Lumen Bioscience Awarded Grant to Develop Nanobody-based Covid-19 Therapeutic
24 Sep 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.